Table 4. SIRs for different follow–up intervals in type 2 diabetes patients from 2007 to 2013.

Site of cancer	Total			≤5 (years)			5–7 (years)
	N	SIR	95% CI	N	SIR	95% CI	N	SIR	95% CI
All cancer	7,435	1.19	1.17–1.22	5,450	3.19	3.11–3.28	1,985	2.08	1.99–2.17
Lung	1,326	1.09	1.03–1.15	974	2.93	2.75–3.12	352	1.89	1.70–2.10
Liver	861	1.32	1.23–1.41	598	3.34	3.08–3.62	263	2.62	2.32–2.96
Gallbladder	87	1.71	1.38–2.11	64	4.59	3.59–5.86	23	2.94	1.96–4.43
Stomach	729	0.92	0.85–0.98	524	2.40	2.21–2.62	205	1.68	1.47–1.93
Colon	413	1.40	1.27–1.55	292	3.63	3.23–4.07	121	2.68	2.25–3.21
Rectum	366	1.26	1.14–1.40	284	3.58	3.18–4.02	82	1.84	1.49–2.29
Esophagus	209	0.76	0.66–0.87	140	1.85	1.57–2.18	69	1.63	1.29–2.06
Small intestine	47	1.42	1.07–1.89	32	3.54	2.50–5.01	15	2.96	1.79–4.92
Pancreas	540	3.14	2.89–3.42	420	8.92	8.11–9.82	120	4.55	3.81–5.45
Breast	396	1.01	0.92–1.12	289	2.70	2.41–3.03	107	1.79	1.48–2.16
Thyroid	301	1.04	0.93–1.13	243	3.07	2.71–3.48	58	1.31	1.01–1.69
Prostate	213	1.78	1.55–2.03	158	4.81	4.12–5.63	55	2.99	2.30–3.90
Bladder	158	1.23	1.06–1.44	115	3.28	2.73–3.94	43	2.19	1.62–2.95
Kidney	118	1.64	1.37–1.97	90	4.58	3.72–5.63	28	2.54	1.76–3.68
Ovary	71	1.07	0.85–1.36	47	2.60	1.95–3.46	24	2.37	1.59–3.53
Cervix	115	0.68	0.57–0.82	91	1.97	1.60–2.42	24	0.93	0.62–1.38
Endometrium	95	1.68	1.38–2.06	70	4.53	3.59–5.73	25	2.89	1.95–4.28
Skin	60	1.06	0.82–1.36	50	3.22	2.44–4.25	10	1.15	0.62–2.14
Non-Hodgkin’s lymphoma	61	1.10	0.85–1.41	43	2.83	2.10–3.81	18	2.11	1.33–3.36
Nasopharynx	84	0.93	0.75–1.15	65	2.62	2.05–3.34	19	1.37	0.87–2.15
Brain	110	1.13	0.93–1.36	75	2.80	2.24–3.52	35	2.34	1.68–3.26

Bold type indicates that the CI does not include the null.

Abbreviations: N, observed number of cases; SIR, standardized incidence ratio; CI, confidence interval.